Timus
Basic Information
- Stock Code
- 4891
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Tokyo
- Establishment Year
- February 2005
- Listing Year
- November 2022
- Official Website
- https://www.tms-japan.co.jp/ja/index.html
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- GNI Group, Heartseed, Nexela Pharma, Medorex, PeptiDream, SanBio, Helios, Fanpep, RenaScience, QualiPs, Takara Bio, TB Group, Japan Tissue Engineering
Overview
Timus is a bio drug discovery venture in the pharmaceutical industry established in 2005, focusing on the development of acute-phase cerebral infarction treatments and aiming to create new drugs.
Current Situation
Timus is primarily advancing the development of treatments for acute-phase cerebral infarction patients and has a drug candidate expected to enter commercialization in 2024 after reaching the final clinical trial phase. Based in Tokyo, it leverages bio drug discovery technology to focus on highly specialized new drug research. Amid expectations of listing in 2025 or later, it is actively pursuing collaborations with related stocks and capital raising. In the midst of intensifying competition with rivals, it strives to build superiority in specific cerebral infarction treatment areas and is promoting technology development through partnerships with other bio ventures. On the funding side, it is strengthening its financial base by expanding R&D expenses through capital increases such as stock acquisition rights issuance. As a social contribution, it aims to reduce the burden on medical sites with the goal of early practical application of safe, high-efficacy treatments. In the future, it envisions business expansion through product commercialization after new drug approval and overseas deployment. Technological innovations and regulatory trends will greatly impact business growth, so it continues to focus on introducing the latest technologies and understanding market needs.
Trivia
Interesting Facts
- One of the few companies specialized in treatment drug development for acute-phase cerebral infarction.
- Bio venture that achieved Tokyo Stock Exchange Mothers listing in 20 years since founding.
- Succeeded in developing patented biomarker.
- Advancing sophistication of drug discovery processes using AI technology.
- Highly evaluated as a medical research base in Tokyo.
- Achieved stable funding through stock acquisition rights issuance.
- Conducting numerous joint research projects with related companies, strong in technology collaboration.
- Focusing on nurturing specialized talent in drug discovery field.
- Capable of completing clinical trial drug manufacturing and development in-house.
- Active research aiming for new drug creation for refractory cerebrovascular diseases.
Hidden Connections
- Exploring drug discovery collaborations with IT companies like Axelmark to pioneer digital health field.
- Strengthening bridge between basic research and clinical application for cerebral infarction through collaboration with Tohoku University.
- Ongoing technology information exchange with peers like TB Group and Fanpep.
- Gaining certain recognition among investors as a bio stock, improving funding capabilities.
- Planning business alliance with major pharmaceutical companies to prepare for commercialization phase.
- Participating in medical and health promotion projects with local governments.
- Closely cooperating with multiple clinical research organizations for clinical trial advancement.
- International patent applications with overseas market entry in view.
Future Outlook
Growth Drivers
- Increasing market demand for acute-phase cerebral infarction treatments
- Evolution and expanded application of bio drug discovery technology
- Tailwinds from domestic and international medical deregulation
- Development efficiency gains from AI and digital technology
- Expansion of strategic alliances with pharmaceutical companies
- Accelerated medical infrastructure development in emerging markets
- Increase in neurological disease patients due to aging society
- Expanding demand for clinical trial support services
- Stabilization of funding environment
- Sustainable securing of R&D talent
- Government medical innovation support measures
- Application potential of regenerative medicine technology
Strategic Goals
- Obtain domestic and international approval for acute-phase cerebral infarction treatment drug and commercialize
- Cultivate pharmaceutical pipeline with sales exceeding 10 billion yen
- Improve drug discovery efficiency by 50% using AI technology
- Establish collaboration system with multiple partner companies
- Improve ESG ratings and build sustainable research framework
- Medical environment improvement through co-creation with local communities
- Launch overseas expansion of clinical trial support business
- Promote multifaceted development of new treatment drug candidates
- Strengthen intellectual property rights and continuous acquisition
- Commercialize high-performance API manufacturing technology
Business Segments
Drug Discovery Partner Services
- Overview
- Provides drug discovery support technologies and molecular information to pharmaceutical companies and research institutions.
- Competitiveness
- High-precision drug development capabilities specialized in acute-phase cerebral infarction
- Customers
-
- Pharmaceutical companies
- Bio ventures
- University research institutions
- Medical institutions
- Products
-
- Joint R&D bio technologies
- Provision of new drug candidate molecules
- Drug discovery support data analysis
Pharmaceutical API Manufacturing
- Overview
- Provides synthesis and supply services for pharmaceutical APIs and intermediates.
- Competitiveness
- Advanced quality control technology and stable supply system
- Customers
-
- Pharmaceutical manufacturers
- Reagent sales companies
- Research facilities
- Products
-
- Pharmaceutical raw material synthesis APIs
- Intermediate compounds
Clinical Trial & Testing Support
- Overview
- Business segment specializing in clinical trial drug manufacturing and clinical trial support.
- Competitiveness
- Latest clinical trial drug development technology and regulatory compliance capabilities
- Customers
-
- Pharmaceutical companies
- CROs
- Clinical research organizations
- Products
-
- Clinical trial drug manufacturing
- Clinical data management
- Regulatory compliance consulting
IP & Technology Licensing
- Overview
- Provides proprietary technology patent licensing and technology transfer support.
- Competitiveness
- Abundant drug discovery patents and strong negotiation capabilities
- Customers
-
- Pharmaceutical companies
- Bio-related companies
- Research institutions
- Products
-
- Patent technology provision
- Technology transfer support
Bio Reagent Sales
- Overview
- Business division providing a wide range of gene-related research reagents.
- Competitiveness
- Diverse lineup of high-performance reagents
- Customers
-
- University labs
- Pharmaceutical research institutes
- Bio research institutions
- Products
-
- Gene research reagents
- Diagnostic reagents
Competitive Advantage
Strengths
- Advanced bio drug discovery technology
- Specialization in acute-phase cerebral infarction treatment
- Flexible R&D structure
- Strong collaboration relationships with related companies
- Improved capital raising capabilities
- Specialized pharmaceutical development expertise
- Accumulated clinical trial track record
- Customer-oriented technology provision
- Abundant specialized research personnel
- Established R&D infrastructure
- Number of patented technologies
- Research base located in central Tokyo
- Rapid decision-making structure
- Expanded market recognition post-IPO
- Utilization of diverse sales channels
Competitive Advantages
- Successful development of proprietary candidate drug in acute-phase cerebral infarction field
- Differentiation from competitors through numerous intellectual property rights
- Close to market entry with progression to final clinical trials
- Efficient organization focused on R&D
- Joint research and technology collaborations with diverse companies
- In-house capability for clinical trial drug manufacturing and support
- Utilization of diverse funding methods such as stock acquisition rights
- Technology accumulation via strong expert network
- Strengthened basic research through university and institution partnerships
- Rapid response to new projects with flexible business expansion
- Synergy creation through technology exchange with related stocks
- Improved brand recognition in bio-related market
- Expectations for exclusive market post-drug approval in specialized area
- Leading competitors in clinical development speed
- Enhanced credibility through Tokyo Stock Exchange listing
Threats
- Development risks and uncertainties until new drug approval
- Emergence of domestic and international rival bio ventures
- Impact from fluctuations in funding environment
- Potential stricter reviews by regulatory authorities
- Increased IP litigation risks
- Risk of development halt due to clinical trial results
- Intensifying price competition post-market entry
- Risk of failing to keep up with pace of technological innovation
- Technology leakage risks from new entrants
- Increased R&D costs due to exchange rate fluctuations
- Impact of new pharmaceutical regulation revisions
- Delayed response to changes in market patient needs
Innovations
2024: Final Clinical Trial Start for Acute-phase Cerebral Infarction Treatment Drug
- Overview
- Completed Phase 1 clinical trial for new neuroprotective drug and initiated final phase trials.
- Impact
- Achieved key milestone toward market entry
2023: New Biomarker Discovery
- Overview
- Discovered proprietary biomarker for early cerebral infarction diagnosis and obtained patent.
- Impact
- Improved accuracy and efficiency of drug discovery
2022: AI Drug Discovery Platform Introduction
- Overview
- Utilized AI to accelerate and enhance precision in candidate compound exploration for drug discovery.
- Impact
- Candidate discovery speed improved by 50%
2021: Expansion of Clinical Trial Drug Manufacturing Facilities
- Overview
- Enhanced manufacturing capacity for clinical trial pharmaceuticals to accelerate development speed.
- Impact
- Succeeded in shortening clinical trial periods
2020: Start of International Joint Research
- Overview
- Initiated joint research on cerebral infarction drug discovery with overseas universities, eyeing global expansion.
- Impact
- Promotes international technology exchange and collaboration
Sustainability
- Development of low-environmental-impact manufacturing processes
- Building a high-safety pharmaceutical supply system
- Continuous participation in regional medical support activities
- Promotion of renewable energy use
- Employee health management and comfortable work environment improvement
- Maintenance of transparent information disclosure system
- Proper management of research data and ethics compliance
- Strengthened proper treatment of manufacturing waste
- Support for resolving information disparities in medical field
- ESG promotion collaboration with partners